Hydroxychloroquine Questions

from Axios Re:Cap · host Axios

Hydroxychloroquine has evolved from a sleepy anti-malaria drug into a partisan litmus test over the future of COVID-19 treatment. Dan and Axios healthcare reporter Bob Herman dig into what we know about the drug, what we still don't, and why both matter. PLUS: New money for small businesses and a way to help New York medical workers

Episode metadata supplied by the publisher feed · Published Apr 9, 2020

Embed this episode

Attribution link and audio player

Ready to play

Hydroxychloroquine Questions

0:00 9:26

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

Small Caps Canada Small Caps Canada The Small Caps podcast keeps stock market investors informed with the latest news by interviewing directors of Canadian listed small cap companies and financial market analysts

Frequently Asked Questions

How long is this episode of Axios Re:Cap?

This episode is 9 minutes long.

When was this Axios Re:Cap episode published?

This episode was published on April 9, 2020.

Can I download this Axios Re:Cap episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!